Brokerages expect Xencor Inc (NASDAQ:XNCR) to post sales of $15.65 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Xencor’s earnings. The lowest sales estimate is $10.30 million and the highest is $21.00 million. Xencor reported sales of $6.44 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 143%. The firm is scheduled to announce its next earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that Xencor will report full-year sales of $15.65 million for the current year, with estimates ranging from $25.30 million to $45.77 million. For the next year, analysts expect that the company will post sales of $25.33 million per share, with estimates ranging from $19.80 million to $36.20 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Xencor.
Xencor (NASDAQ:XNCR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.04). Xencor had a negative net margin of 148.29% and a negative return on equity of 15.26%.
In other news, major shareholder John S. Stafford III purchased 9,215 shares of Xencor stock in a transaction dated Thursday, December 14th. The stock was acquired at an average cost of $20.76 per share, for a total transaction of $191,303.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder John S. Stafford III purchased 5,349 shares of Xencor stock in a transaction dated Friday, November 24th. The shares were purchased at an average price of $19.85 per share, with a total value of $106,177.65. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 36,153 shares of company stock valued at $731,583. 4.03% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. Virginia Retirement Systems ET AL lifted its holdings in Xencor by 10.0% in the 3rd quarter. Virginia Retirement Systems ET AL now owns 76,200 shares of the biopharmaceutical company’s stock worth $1,747,000 after purchasing an additional 6,900 shares during the last quarter. State Street Corp lifted its holdings in Xencor by 11.1% in the 2nd quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock worth $23,295,000 after purchasing an additional 110,474 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Xencor by 5.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock worth $35,913,000 after purchasing an additional 90,094 shares during the last quarter. Northern Trust Corp lifted its holdings in Xencor by 6.6% in the 2nd quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock worth $10,527,000 after purchasing an additional 30,715 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in Xencor by 87.4% in the 3rd quarter. GSA Capital Partners LLP now owns 72,700 shares of the biopharmaceutical company’s stock worth $1,666,000 after purchasing an additional 33,900 shares during the last quarter. Institutional investors and hedge funds own 77.50% of the company’s stock.
Xencor (NASDAQ:XNCR) opened at $21.71 on Friday. Xencor has a 12 month low of $18.55 and a 12 month high of $28.64. The firm has a market capitalization of $1,020.00, a PE ratio of -21.50 and a beta of 1.97.
TRADEMARK VIOLATION WARNING: “Xencor Inc (XNCR) Expected to Announce Quarterly Sales of $15.65 Million” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/09/xencor-inc-xncr-expected-to-announce-quarterly-sales-of-15-65-million.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.